Physician profile
Donna Clair Orvin
NPI 1699712539
$4,940.62
in general payments reported to CMS, 2019-2025
16 companies · $317 in 2025
The $317 reported for 2025 was more than what a typical Psychiatry provider received nationally (typical 2025 total: $176).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $2,286 · 2020: $522 · 2022: $481 · 2023: $865 · 2024: $469 · 2025: $317.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,651.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,651.31 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Teva Pharmaceuticals USA, INC. | $915.35 | 2019-2023 | Austedo, Uzedy |
| Janssen Pharmaceuticals, INC | $743.81 | 2019-2024 | Invega Sustenna, Invega Trinza, Spravato |
| Alkermes, INC. | $722.84 | 2019-2025 | Lybalvi, Aristada, Aristada Initio |
| Neurocrine Biosciences, INC. | $705.79 | 2019-2024 | Ingrezza |
| Sunovion Pharmaceuticals INC. | $575.33 | 2019 | |
| Otsuka America Pharmaceutical, INC. | $379.08 | 2019-2025 | Rexulti |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $223.99 | 2023-2024 | Caplyta |
| Allergan, INC. | $203.25 | 2019-2020 | |
| E.R. Squibb & Sons, L.L.C. | $132.41 | 2024-2025 | Cobenfy |
| Otsuka Pharmaceutical Development & Commercialization, INC. | $102.95 | 2019 | |
| Almatica Pharma LLC | $66.35 | 2024-2025 | Loreev Xr |
| Abbvie INC. | $61.80 | 2023-2024 | |
| Vanda Pharmaceuticals INC. | $38.21 | 2019-2025 | Fanapt, Hetlioz |
| Axsome Therapeutics, INC. | $24.21 | 2023 | Auvelity |
| Lundbeck LLC | $22.76 | 2019 |
Show all 16 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Jazz Pharmaceuticals INC. | $22.49 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Donna Orvin listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.